Substancia activa Dapaglifozina 10mg
via de administracion oral
promocion valida del 25 marzo al 15 abril 2025 pago en efectivo y solo en sucursal
Monotherapy: FORXIGA® is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). Add-on Therapy: FORXIGA® is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione, a sulfonylurea (with or without metformin), a DPP4 inhibitor (with or without metformin), or insulin (alone or in combination with up to two oral antidiabetic agents) when existing therapy, along with diet and exercise, does not provide adequate glycemic control. Initial Combination: FORXIGA® is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual therapy with dapagliflozin and metformin is appropriate.
